Articles tagged "Rejection"

2022 American Transplant Congress
A Sign of Things to Come? Clinical Markers After Elevated Donor-Derived Cell-Free DNA in Heart Transplant Recipients
D. T. Kim¹, E. J. Henricksen², B. M. Zhang³, J. J. Teuteberg¹, Y. Moayedi⁴, H. I. Luikart¹, J. Han⁵, B. Wayda¹, K. Khush¹
¹Cardiology, Stanford University, Stanford, CA, ²Transplant, Stanford Health Care, Stanford, CA, ³Pathology, Stanford University, Stanford, CA, ⁴Cardiology, University Health Network, Toronto, ON, Canada, ⁵Cardiology, University of Chicago, Chicago, IL
*Purpose: Endomyocardial biopsy (EMBx) has historically been the standard of care for surveillance post heart transplant (HTx), but is limited by sample area and interpretation.…
2022 American Transplant Congress
Characterization of Kidney Allograft Pathology Using the Histomap Gene Expression Profile (GEP) and Formalin Fixed Paraffin Embedded (FFPE) Tissue
N. Garg¹, K. Degner², H. Zhang³, W. Tian³, F. Aziz⁴, S. Parajuli², W. Zhong², N. Wilson², S. Panzer¹, A. Djamali²
¹University of Wisconsin Madison, Madison, WI, ²University of Wisconsin, Madison, WI, ³CareDx, Brisbane, CA, ⁴University of Wsiconsin, Madison, WI
*Purpose: The new Banff Human Organ Transplant (B-HOT) gene panel assessed on nCounter system has been created through a collaboration between NanoString and the Banff…
2022 American Transplant Congress
Defining New Arterial and Arteriolar Lesions Accompanying Transplant Glomerulopathy: Potential Additions to the Histologic Assessment of ABMR
A. Perkowska-Ptasinska¹, D. Deborska-Materkowska², M. Ciszek³, M. Myslak⁴, J. Chang⁵, J. Reeve⁶, P. Halloran⁷
¹Pathology, Medical University of Warsaw, Warsaw, Poland, ²Transplantation Medicine, Nephrology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland, ³Immunology, Transplantation Medicine and Internal Diseases, Medical University of Warsaw, Warsaw, Poland, ⁴Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University, Szczecin, Poland, ⁵Alberta Transplant Applied Genomics Center, Edmonton, AB, Canada, ⁶Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ⁷Pathology, Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, AB, Canada
*Purpose: Transplant glomerulopathy (TG) results from chronic endothelial injury most commonly related to ABMR. Surprisingly, except for PTC, the relation between TG and other vascular…
2022 American Transplant Congress
Regulatory T and B Cell Responses Are Equally Compromised During Antibody-Mediated Rejection of Kidney Allografts
K. Louis¹, P. Fadakar², C. Macedo², M. Yamada², M. Lucas², X. Gu², A. Zeevi², P. Randhawa², C. Lefaucheur³, D. Metes²
¹Inserm U976, Human Immunology and Immunopathology, Paris, France, ²Surgery, University of Pittsburgh, Pittsburgh, PA, ³Inserm U970, Paris Translational Research Center for Organ Transplantation, Paris, France
*Purpose: Although considerable advances have been made in understanding the cellular effector mechanisms responsible for donor-specific antibody (DSA) generation leading to antibody-mediated rejection (ABMR), the…
2022 American Transplant Congress
Clinical Validation of Automated Urinary Chemokine Assays for Non-Invasive Detection of Kidney Transplant Rejection: A Large Prospective Cohort Study
E. Van Loon¹, C. Tinel¹, J. Callemeyn¹, M. Coemans¹, A. Van Craenenbroeck¹, T. Vaulet², D. Anglicheau³, M. Naesens¹
¹Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium, ²ESAT STADIUS Center for Dynamical Systems, KU Leuven, Leuven, Belgium, ³Department of Nephrology and Kidney Transplantation, Necker Hospital, Paris, France
*Purpose: Non-invasive diagnostic markers for kidney transplant rejection can provide useful information but often do not reach the clinical implementation stage. The chemokines CXCL9 and…
2022 American Transplant Congress
Modern Medicine Needs Modern Technology Tools
Z. S. Soltani,, S. Soltani
Ochsner Foundation Hospital, New Orleans, LA
*Purpose: Dd-cfDNA has been used as a non-invasive biomarker for allograft injury and has been shown to detect subclinical rejection with higher predictive power compare…
2022 American Transplant Congress
Can dd-cf DNA Eliminate Unnecessary Biopsies? The Answer is Yes!
K. Andreoni, Y. Chalicheemala, M. Debroy, M. Maklad, K. Zhao, M. Aeder, A. Jittirat, D. Ecabert, A. Bixby, C. Burrelli, K. Chavin
University Hospitals Cleveland Medical Center, Cleveland, OH
*Purpose: Historically our center has been one that routinely performs biopsies. We perform them pre-perfusion, for slowly recovering allografts between day 10-14, and routinely at…
2022 American Transplant Congress
Optimizing Kidney Transplant Immunosuppression Using a Phenotypic Personalized Dosing Model
J. F. Bruner¹, N. Padmanabhan², C. Ho², A. Zarrinpar¹
¹Surgery, University of Florida, Gainesville, FL, ²Bioengineering, University of California, Los Angeles, Los Angeles, CA
*Purpose: Immunosuppression is essential for preventing rejection and promoting long-term graft survival following solid organ transplantation; it also places patients at risk for infection and…
2022 American Transplant Congress
Evaluating Long Term Outcomes in Kidney Transplant Patients with TruGraf Gene Expression and TRAC Dd-cfdna in the TRULO Study
P. West-Thielke, W. Ally, J. Hickey, L. Stach, J. Fleming, T. Cober, A. Kawano, I. Agboli, C. Miller, J. Holman
Eurofins Transplant Genomics, Framingham, MA
*Purpose: The aim of this study is to evaluate long term clinical outcomes in kidney transplant patients undergoing non-invasive rejection monitoring with the OmniGraf® biomarker…
2022 American Transplant Congress
Early Detection of Acute Rejection by Urine QSant is Not Confounded by Post-Transplant Time
C. Baan¹, S. Ghosh², J. Verhoeven¹, D. Hesselink¹, K. Boer¹, M. Sarwal²
¹Erasmus MC, Rotterdam, Netherlands, ²NephroSant, Brisbane, CA
*Purpose: We explore the viability of urinary biomarker-based monitoring for rejection in early days following renal transplantation.*Methods: Patients are from the Erasmus MC and received…